Johnson & Johnson $JNJ Shares Acquired by Ferguson Wellman Capital Management Inc.

Key Points

• Ferguson Wellman Capital Management increased its Johnson & Johnson stake by 41% in the third quarter, acquiring 193,905 shares for a total holding of 666,675 shares valued at approximately $176.5 million.
• Analysts maintain a positive outlook, with Johnson & Johnson receiving a consensus “Moderate Buy” rating and an average price target of $275.87; several firms recently raised their targets, including HSBC to $320.
• JNJ shares recently fell 0.8% to $254.07, while the company reported quarterly earnings and revenue above expectations and paid a quarterly dividend of $1.34 per share, representing a 2.1% yield.

Ferguson Wellman Capital Management Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 41.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 666,675 shares of the company's stock after purchasing an additional 193,905 shares during the period. Johnson & Johnson makes up 2.1% of Ferguson Wellman Capital Management Inc.'s portfolio, making the stock its 11th biggest position. Ferguson Wellman Capital Management Inc.'s holdings in Johnson & Johnson were worth $176,495,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Adelphi Trust Co lifted its stake in shares of Johnson & Johnson by 5.1% during the third quarter. Adelphi Trust Co now owns 1,950 shares of the company's stock valued at $516,000 after acquiring an additional 95 shares during the period. Eastern Bank grew its holdings in shares of Johnson & Johnson by 105.9% in the 3rd quarter. Eastern Bank now owns 299,306 shares of the company's stock valued at $79,238,000 after acquiring an additional 153,938 shares in the last quarter. Polaris Financial Partners bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $56,000. Boltwood Capital Management raised its position in shares of Johnson & Johnson by 2.5% in the third quarter. Boltwood Capital Management now owns 4,733 shares of the company's stock valued at $1,253,000 after purchasing an additional 115 shares during the period. Finally, CX Institutional boosted its position in shares of Johnson & Johnson by 113.4% in the third quarter. CX Institutional now owns 64,782 shares of the company's stock valued at $17,150,000 after acquiring an additional 34,418 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the topic of a number of research analyst reports. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Guggenheim lifted their price target on Johnson & Johnson from $270.00 to $287.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. TD Cowen raised their target price on Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Weiss Ratings raised shares of Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, July 24th. Finally, HSBC boosted their target price on Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $275.87.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 33,597 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company's stock, valued at $5,779,963.81. This represents a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last 90 days. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Down 0.8%

JNJ traded down $1.96 during trading on Monday, reaching $254.07. The stock had a trading volume of 3,741,572 shares, compared to its average volume of 7,973,521. The stock's 50 day moving average is $266.37 and its two-hundred day moving average is $248.40. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $612.28 billion, a price-to-earnings ratio of 29.43, a P/E/G ratio of 2.52 and a beta of 0.21. Johnson & Johnson has a one year low of $182.94 and a one year high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion for the quarter, compared to analysts' expectations of $25.06 billion. During the same quarter in the prior year, the company posted $2.77 earnings per share. The business's revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts expect that Johnson & Johnson will post 11.54 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson's payout ratio is presently 62.11%.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.